Rosuvastatin-based combination treatment with acetylsalicylic acid or ezetimibe in the management of patients at high and very high cardiovascular risk. Expert opinion paper of the Polish Lipid Association 2025

Rosuvastatin-based combination treatment with acetylsalicylic acid or ezetimibe in the management of patients at high and very high cardiovascular risk. Expert opinion paper of the Polish Lipid Association 2025

Lipid disorders are the most common risk factor for atherosclerotic cardiovascular disease (ASCVD) in Poland, where it is responsible for up to 200,000 deaths per year, with the number of myocardial infarctions and strokes reaching 80,000 annually and 25% of people dying within 3 years after a myoca...

Full description

Saved in:
Bibliographic Details
Main Authors: Maciej Banach, Stanisław Surma, Agata Bielecka-Dąbrowa, Marek Gierlotka, Renata Główczyńska, Piotr Jankowski, Jacek Jóźwiak, Jacek Kubica, Witold Streb, Filip M. Szymański, Tomasz Tomasik, Robert Gil
Format: Article
Language:English
Published: Termedia Publishing House 2025-01-01
Series:Archives of Medical Science
Subjects:
cardiovascular risk
rosuvastatin
ezetimibe
acetylsalicylic acid
primary and secondary prevention
combination therapies
Online Access:https://www.archivesofmedicalscience.com/Rosuvastatin-based-combination-treatment-with-acetylsalicylic-acid-or-ezetimibe-in,199826,0,2.html
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.archivesofmedicalscience.com/Rosuvastatin-based-combination-treatment-with-acetylsalicylic-acid-or-ezetimibe-in,199826,0,2.html

Similar Items